Company intelligence / Profile preview

Integrity Applications

Ashdod, Southern, Israelintegrityapps.com ↗

Ownership: Public · GCTK
Development stage: Commercial

Overview

GlucoTrack®, their flagship non-invasive glucose monitoring device, has received regulatory approval in several countries including South Korea. The device is designed for people with Type 2 diabetes or at risk of developing diabetes and does not require finger pricking. It uses multiple sensor technologies clipped to the earlobe and provides real-time glucose readings via proprietary algorithms. Initial clinical studies have supported its use as an alternative to invasive blood glucose monitoring for certain populations.

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Wistron Corporation – manufacturing partnership for GlucoTrack devices.South Korean distribution partner – commercial launch partner in South Korea.

Beyond the preview

Go deeper on Integrity Applications.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrity Applications.

Explore the full profile